Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00750 (
PLA
)
16,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Plasmin is a labile enzyme destroyed by a process termed autodigestion. Studied by a kinetic assay on the substrate Tos-
Gly
-Pro-Lys-pNA this process is shown to follow a bimolecular mode of reaction, which is retarded by plasmin degradation products. Plasmin is protected by fibrinogen, by epsilon-aminocaproic acid (6-aminohexanoic acid), by increasing ionic strength, and by glycerol. CNBr fragments of fibrinogen did not protect. Lack of substrate protection of plasmin may give rise to errors in a two-stage
plasminogen activator
assay, while the presence of substrate in a one-stage method prevents degradation of the generated plasmin.
...
PMID:The autodigestion of human plasmin follows a bimolecular mode of reaction subject to product inhibition. 293 86
A one-chain recombinant
tissue-type plasminogen activator
(EC 2.4.31.-) (tPA) analogue was constructed in which Arg-275 of the activation site was changed to
Gly
by site-directed mutagenesis. This analogue, tPA-Gly275, was very resistant to plasmin (EC 2.4.21.5) cleavage. It has been used to gain information about the activity of the uncleaved one-chain tPA form, also when plasmin is generated as a result of a plasminogen activation reaction. The amidolytic activity of tPA-Gly275 with less than Glu-
Gly
-Arg-pNA was investigated and compared to that of one-chain and two-chain wild-type recombinant tPA. A small but significant intrinsic amidolytic activity was observed with the analogue as well as the wild-type one-chain tPA form. However, it was much lower than that of two-chain tPA. Polymerised fibrin enhanced the amidolytic activity of both one-chain tPA forms but not of two-chain tPA. Measurements of the plasminogen activation kinetics in the absence of fibrin revealed that tPA-Gly275 possessed a significant intrinsic activity. However, it was 30-fold lower than that of two-chain tPA. Addition of polymerised fibrin profoundly enhanced the plasminogen activation rate of both tPA-Gly275 and wild-type one- and two-chain tPA to approximately the same maximal level. The results were interpreted to mean that fibrin binding can induce an activated state of the intact tPA one-chain form.
...
PMID:The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage. 296 43
The purpose of these studies was to identify some of the extracellular proteolytic enzymes associated with the development and healing of acute inflammatory lesions. Lesions were produced in the skin of rabbits by the topical application of the military vesicant, sulfur mustard (SM). Full-thickness, 1-cm2 central biopsies of the lesions were organ-cultured for one to three days, and the culture fluids were assayed for proteases with a variety of substrates. When compared to culture fluids from normal skin, the culture fluids from both developing and healing SM lesions had three to six times the levels of proteases hydrolyzing two synthetic peptide substrates: (1) t-butyloxycarbonyl-Leu-
Gly
-Arg-4-trifluoromethylcoumarin-7-amide(Boc-Leu -
Gly
- Arg-AFC, herein abbreviated LGA-AFC), and (2) N-benzoyl-phenylalanine-beta-naphthyl ester (BPN). LGA-AFC is a substrate for trypsin, plasmin,
plasminogen activator
, thrombin, kallikrein, and the C3 and C5 convertases; BPN is a chymotrypsin and cathepsin G substrate. The culture fluids did not consistently hydrolyze four other synthetic peptide substrates or the proteins [14C]-casein and [14C]elastin. In order to determine the likely sources of LGA-AFCase and BPNase activity, we counted the number of granulocytes (PMNs), macrophages (MNs) and activated fibroblasts in histologic sections of developing and healing SM lesions, and we measured the levels of these enzymes in serum, in culture fluids of PMN and MN peritoneal exudate cells, and in culture fluids of two fibroblast cell lines. In SM lesions, serum and fibroblasts seemed to be the major source of LGA-AFCase, and serum alone the major source of BPNase. Tissue PMNs and MNs seemed to be only minor sources. The crusts of healing lesions, which were full of dead PMNs, seemed to be a rich source of both enzymes. In the SM lesion culture fluids, whether LGA-AFC and BPN were hydrolyzed by endopeptidases or only by exopeptidases could be determined by evaluating complex formation with alpha-macroglobulin proteinase inhibitors (alpha M). Endopeptidases, but not exopeptidases, are entrapped and inhibited by alpha M, because an internal peptide band in alpha M must first be hydrolyzed before molecular rearrangement (required for proteinase inhibition) occurs. The catalytic site of endopeptidases that are entrapped and inhibited by alpha M is known to remain active on (and reachable by) small synthetic peptide substrates such as LGA-AFC and BPN.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Proteases released in organ culture by acute dermal inflammatory lesions produced in vivo in rabbit skin by sulfur mustard: hydrolysis of synthetic peptide substrates for trypsin-like and chymotrypsin-like enzymes. 304 42
A urokinase-type plasminogen activator was purified from conditioned media of several human cell cultures, but preferably from the human lung adenocarcinoma line CALU-3 (ATCC, HTB-55), using a combination of chromatography on zinc chelate-Sepharose, SP-Sephadex C-50, and Sephadex G-100. Final yields of 65-100 micrograms/liter of starting material were obtained with a 290-fold purification factor and a recovery of 30%. The purified
plasminogen activator
consists of a single polypeptide chain with Mr 54,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and is very similar or identical to single-chain urokinase-type plasminogen activator on the basis of immunodiffusion, amino acid composition, and the lack of specific binding to fibrin. It has very low amidolytic activity on Pyroglu-
Gly
-Arg-rho-nitroanilide and is converted to two-chain urokinase by limited exposure to plasmin. It has a specific activity of 60,000 IU/mg on fibrin plates and directly activates plasminogen following Michaelis-Menten kinetics with Km = 1.1 microM and kappa cat = 0.0026 S-1. It is concluded that the
plasminogen activator
purified from CALU-3-conditioned media is physically and kinetically identical to single-chain urokinase-type plasminogen activator. With the present straightforward purification method and a readily available source, sufficient amounts of single-chain urokinase-type plasminogen activator can be obtained for more detailed investigations of its biochemical, biological, and thrombolytic properties.
...
PMID:Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. 308 Apr 23
After taking the local Japanese spirit 'Shochu', 'Sake' and beer, increased plasma fibrinolysis was confirmed in normal persons at about 1 hr after for both the pyro-Glu-
Gly
-Arg-pNA amidolytic and Glu-plasminogen activating activities in eluates from [N alpha-(epsilon-aminocaproyl)-DL-homoarginine hexylester;)]-Sepharose affinity column. The activity was highest in the Shochu group, followed by the Sake and beer groups with an approximately 2.1-, 1.7- and 1.5-fold increase in fibrinolytic activity, respectively, compared to the control. The enzyme could be further purified using urokinase-IgG-Sepharose immunoadsorbent column from the Shochu group and it reacted with and was inhibited by urokinase specific antibody. The main molecular weight of the active enzyme was about 30,000, and those of minor components were about 50,000 and 100,000, as determined by zymography. These findings suggest that some of the enzymes appearing in the plasma after drinking are related to 'urokinase-like
plasminogen activator
', being endogenously produced.
...
PMID:Urokinase-like plasminogen activator increased in plasma after alcohol drinking. 312 90
A gene coding for the bacterial
plasminogen activator
staphylokinase (SAK) was cloned from Staphylococcus aureus bacteriophage 42D into an exoprotease reduced mutant strain of Bacillus subtilis (1). Yields of up to 50 mg SAK per litre of culture supernatant were obtained depending on the medium used. SAK purified by ion exchange chromatography and gel filtration had a specific activity of 16,000 units/mg protein. Isoelectric focusing of the purified SAK revealed heterogeneity with respect to the isoelectric points. Four different SAK proteins were identified among which the majority fraction had an IEP of 6.3 and a N-terminal amino acid sequence of NH2-Lys-
Gly
-Asp ... This N-terminus was 10 amino acids downstream of the expected signal peptide cleavage site beyond AA 27. It resulted most likely from a postsecretory proteolytic modification of the transiently appearing and correct processing product. In contrast to other plasminogen activators SAK was found to be resistant to proteolytic inactivation by plasmin.
...
PMID:Purification and characterization of the bacterial plasminogen activator staphylokinase secreted by a recombinant Bacillus subtilis. 314 68
The cDNA coding for the porcine pancreatic prophospholipase A2 (proPLA) has been cloned and expressed in E. coli. Expression of proPLA could only be obtained in the form of intracellular aggregates after fusing the 15 kDa proPLA to a large (greater than or equal to 45 kDa) bacterial peptide. The fusion protein was readily purified from cell lysates, and specifically cleaved. Cleavage of the fusion protein was achieved with either hydroxylamine (at Asn/
Gly
sequences in the denatured protein), or trypsin (between the pro- and the mature
PLA
in the renatured fusion protein). The former method releases a proPLA-like enzyme, while the latter directly yields
PLA
. Renaturation of the fusion protein was made possible by the use of a recently reported new S-sulphonation method. The released (pro)
PLA
was purified (yields of 2-3 mg/ltr of culture medium), and showed identical properties compared to native (pro)
PLA
.
...
PMID:Expression of porcine pancreatic phospholipase A2. Generation of active enzyme by sequence-specific cleavage of a hybrid protein from Escherichia coli. 329 82
Plasmin-catalyzed modification of the native plasma zymogen Glu1-plasminogen to its more reactive Lys78 form has been shown to be enhanced in the presence of fibrin. The aim of the present work has been to characterize the influence of fibrinopeptide release, fibrin polymerization, and plasmin cleavage of fibrin on the rate of Lys78-plasminogen formation. 125I-Labeled Glu1- to Lys78-plasminogen conversion was catalyzed by performed Lys78-plasmin, or by plasmin generated during plasminogen activation with tissue plasminogen activator or urokinase. The two forms of plasminogen were quantitated following separation by polyacrylamide gel electrophoresis in acetic acid/urea. Plasmin generated by
plasminogen activator
was monitored by a fixed-time amidolytic assay. The rate of Lys78-plasminogen formation was correlated, in separate experiments, to the simultaneous, plasmin-catalyzed cleavage of 125I-labeled fibrinogen or fibrin to fragments X, Y, and D. The radiolabeled components were quantitated after separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The results show that the formation of both bathroxobin-catalyzed des-A-fibrin and thrombin-catalyzed des-AB-fibrin leads to marked stimulation of Lys78-plasminogen formation, whereas inhibition of fibrin polymerization, with
Gly
-Pro-Arg-Pro, abolishes the stimulatory effect. The rate of Lys78-plasminogen formation varies markedly in the course of fibrinolysis. The apparent second-order rate constant of the reaction undergoes a transient increase upon transformation of fibrin to des-A(B) fragment X polymer and decreases about 10-fold to the level observed during fibrinogenolysis upon further degradation to soluble fragments Y and D.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:The course and prerequisites of Lys-plasminogen formation during fibrinolysis. 338 32
Plasma fibrinolysis in rats rose above the level of physiological fluctuations in a curve with two peaks at 1 and 6 h, following intraduodenal administration of high-molecular-weight urokinase (HMW-UK; MW 53,000; 124,000 IU/mg protein). Activation of plasma fibrinolysis was also confirmed with insolubilized enzyme (glass-coupled UK), but lacked the first activity peak. Plasma fibrinolytic enzyme isolated by affinity chromatography revealed strong fibrinolytic (1,120 IU/dl), pyro-Glu-
Gly
-Arg-pNA amidolytic (3,200 nmol/dl) and Glu-plasminogen activating (24.5 IU/dl) activities. Using specific UK antibody, it appeared that the first peak originated from the administered UK, while the second one derived from endogenous
plasminogen activator
. Dose response of UK was not observed, and the maximal effect was at about 5,000 IU/kg body weight.
...
PMID:Plasma fibrinolysis after intraduodenal administration of urokinase in rats. 405 71
Plasminogen activators from prostate tissue were purified to apparent homogeneity by a procedure involving reverse ammonium sulfate gradient solubilization, chromatography on gelatine-Sepharose, gel filtration on Sephadex G-150, and chromatography on Con A-Sepharose as a final step. Two activators were obtained. The predominant one exhibited physicochemical, immunochemical and functional properties indistinguishable from human urinary high molecular weight urokinase. The other one, which amounted to about 20% was immunochemically related to tissue type
plasminogen activator
and its
plasminogen activator
activity was enhanced by addition of CNBr-fibrinogen fragments in a similar pattern as for the vascular
plasminogen activator
. The molecular weight, however, and enzymatic activities on the synthetic low molecular weight paranitroanilide substrates pyro-Glu-
Gly
-Arg-pNA and H-D-Ile-Pro-Arg-pNA were different to vascular
plasminogen activator
but similar to high molecular weight urinary urokinase.
...
PMID:Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. 619 43
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>